Speaking isn’t just a business – it’s a vehicle for accomplishing what we really need: changing how people think … especially, empowering them to take effective action, to become involved in their health. Here’s a photo from a speech to radiologists, encouraging them to share images with patients:[Read more…]
I keep seeing patterns of thought that I frankly think are pretty benighted. With luck, shedding some light on them will help. This one is so STUCK in darkness that I’ve decided to publish a little series on the subject.
First is this editorial about patients in research. Next will be what happened when a researcher I know became a patient/family member. Then will be how this fits into a century-long timeline of progressing toward patient autonomy … which of course requires a matching increase in patient responsibility.
This is a quick first post to get this online before the meeting finishes. I hope to add more notes below.
I’m in Brussels at the AGM (Annual General Meeting) of the European Cancer Patients Coalition, an association of over 400 cancer patient organizations. They are organized, they’re methodical, they’re action-oriented, working on health policy, drug development processes, patient involvement in clinical trials, and anything else in the patient’s interest. I was invited by Mrs. Kathi Apostilidis, vice president of ECPC and a long-time member of the Society for Participatory Medicine. She is also known as a force of nature.
In September 2016 TrialReach rebranded itself Antidote, to shift focus away from the “solution” (the clinical trial), focusing instead on the patient’s need: “I have a problem, and I need an antidote.”
My advisory client TrialReach is on the big hot TechCrunch site today, for their success in raising another $13.5 million (here). I don’t do much advisory work, but to this one I said yes, because it’s a big push forward in making vital information more accessible to the ultimate stakeholder – the patient – and it’s done in way that blends three things I’m passionate about: good business sense, modern technology, and patient-centered design.
(I don’t have stock in the company – not even a tiny amount; my policy is that I sell advisory services, but I don’t want to be in a position of literally having a stake in how well their stock does. And, as anyone who knows me knows, nobody could pay me enough to say or do something I don’t believe in. So I’m talking about this company because I believe it deserves attention, not as part of any quid pro quo.)